| Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome MN Hossen, L Wang, HR Chinthalapally, JD Robertson, KM Fung, ... Science advances 6 (30), eaba5379, 2020 | 36 | 2020 |
| Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer S Elayapillai, S Ramraj, DM Benbrook, M Bieniasz, L Wang, G Pathuri, ... Gynecologic oncology 160 (1), 302-311, 2021 | 29 | 2021 |
| Patient-derived xenografts of high-grade serous ovarian cancer subtype as a powerful tool in pre-clinical research M Cybula, L Wang, L Wang, AL Drumond-Bock, KM Moxley, ... Cancers 13 (24), 6288, 2021 | 19 | 2021 |
| Gold nanoparticles disrupt the IGFBP2/mTOR/PTEN axis to inhibit ovarian cancer growth MN Hossen, L Wang, SKD Dwivedi, Y Zhang, G Rao, CK Elechalwar, ... Advanced Science 9 (31), 2200491, 2022 | 7 | 2022 |
| Upregulation of Succinate Dehydrogenase (SDHA) Contributes to Enhanced Bioenergetics of Ovarian Cancer Cells and Higher Sensitivity to Anti-Metabolic Agent Shikonin L Wang, M Cybula, M Rostworowska, L Wang, P Mucha, M Bulicz, ... Cancers 14 (20), 5097, 2022 | 7 | 2022 |
| Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor L Wang, L Wang, M Cybula, AL Drumond-Bock, KM Moxley, M Bieniasz Genes & cancer 11 (3-4), 106, 2020 | 4 | 2020 |
| An unbiased seed-based RNAi selection screen identifies small RNAs that inhibit androgen signaling and prostate cancer cell growth JM Corbin, C Georgescu, L Wang, JD Wren, M Bieniasz, C Xu, AS Asch, ... Molecular Therapy-Nucleic Acids 33, 257-272, 2023 | 2 | 2023 |
| Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma AL Drumond-Bock, L Wang, L Wang, M Cybula, M Rostworowska, ... Genes & Cancer 14, 56, 2023 | 2 | 2023 |
| Cloning BRD4 long isoform into overexpression vectors for stable overexpression of BRD4-L in mammalian cells AL Drumond-Bock, M Cybula, L Wang, L Wang, M Bieniasz STAR protocols 3 (4), 101785, 2022 | 1 | 2022 |
| Abstract LB542: Overexpression of the short isoform of Brd4 in ovarian carcinoma leads to highly aggressive tumor phenotype AL Drumond-Bock, L Wang, L Wang, M Cybula, M Rostworowska, ... Cancer Research 82 (12_Supplement), LB542-LB542, 2022 | 1 | 2022 |
| Utilization of patient-derived tumor xenograft (Pdx) models in oncology M Cybula, K Moxley, L Wang, L Wang, M Bieniasz CLINICAL CANCER RESEARCH 25 (22), 84-84, 2019 | 1 | 2019 |
| Efficacy and mechanism of mebendazole for ovarian cancer therapy R Rai, D Penta, D Dey, DM Benbrook, L Wang, M Bieniasz, LE Dockery Cancer Research 84 (6_Supplement), 4671-4671, 2024 | | 2024 |
| Exploiting metabolic vulnerabilities of ovarian cancer with upregulated succinate dehydrogenase L Wang, M Bulicz, P Mucha, M Kinter, A Pranay, TM Griffin, BF Miller, ... Cancer Research 83 (7_Supplement), 6032-6032, 2023 | | 2023 |
| Targeting BMI1 mitigates chemoresistance in ovarian cancer A Dey, SKD Dwivedi, L Wang, MN Hossen, F Neizer-Ashun, M Bieniasz, ... Genes & Diseases 9 (6), 1415-1418, 2022 | | 2022 |
| A NOVEL UNBIASED SEED-BASED RNAi SCREEN IDENTIFIES SMALL RNAs THAT INHIBIT ANDROGEN SIGNALING AND PROSTATE CANCER CELL GROWTH JM Corbin, C Georgescu, L Wang, JD Wren, M Bieniasz, C Xu, AS Asch, ... bioRxiv, 2022.09. 29.510140, 2022 | | 2022 |
| Abstract LB125: The role of succinate dehydrogenase in ovarian cancer metabolism M Cybula, M Rostworowska, L Wang, S Wang, AL Drumond-Bock, ... Cancer Research 82 (12_Supplement), LB125-LB125, 2022 | | 2022 |
| Abstract GMM-021: UTILIZATION OF PATIENT-DERIVED TUMOR XENOGRAFT (PDX) MODELS IN ONCOLOGY M Cybula, K Moxley, L Wang, L Wang, M Bieniasz Clinical Cancer Research 25 (22_Supplement), GMM-021-GMM-021, 2019 | | 2019 |
